Chemical Characteristics of Platycodon grandiflorum and its Mechanism in Lung Cancer Treatment.
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer.
Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, Kaneda H, Hasegawa Y, Tanaka K, Takeda M, Nakagawa K.
JAMA Oncol. 2018 Mar 1;4(3):374-378. doi: 10.1001/jamaoncol.2017.2925.
Cancer prevention with rapamycin.
Blagosklonny MV.
Oncotarget. 2023 Apr 14;14:342-350. doi: 10.18632/oncotarget.28410.
PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer.
Barlesi F, Cho BC, Goldberg SB, Yoh K, Zimmer Gelatti AC, Mann H, Gopinathan A, Bielecka ZF, Newton M, Aggarwal C.
Future Oncol. 2024;20(29):2137-2147. doi: 10.1080/14796694.2024.2354160. Epub 2024 Jul 18.
Treatment of Small Cell Lung Cancer with Lurbinectedin: A Review.
Rajput PS, Khan SR, Singh P, Chawla PA.
Anticancer Agents Med Chem. 2022;22(5):812-820. doi: 10.2174/1871520621666210706150057.
Overcoming lung cancer immunotherapy resistance by combining nontoxic variants of IL-12 and IL-2.
Horton BL, D'Souza AD, Zagorulya M, McCreery CV, Abhiraman GC, Picton L, Sheen A, Agarwal Y, Momin N, Wittrup KD, White FM, Garcia KC, Spranger S.
JCI Insight. 2023 Oct 9;8(19):e172728. doi: 10.1172/jci.insight.172728.
Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities.
Suresh K, Naidoo J, Lin CT, Danoff S.
Chest. 2018 Dec;154(6):1416-1423. doi: 10.1016/j.chest.2018.08.1048. Epub 2018 Sep 4.
Impact of Lung Cancer Treatment on Cognitive Functioning.
van de Kamp HJ, Molder MT, Schulkes KJG, Stellingwerf M, van Elden LJR, van Lindert ASR, Hamaker ME.
Clin Lung Cancer. 2020 Mar;21(2):114-126.e3. doi: 10.1016/j.cllc.2019.06.006. Epub 2019 Jun 15.
Pulmonary toxicity of systemic lung cancer therapy.
Long K, Suresh K.
Respirology. 2020 Nov;25 Suppl 2:72-79. doi: 10.1111/resp.13915. Epub 2020 Jul 29.
Effect of Coronavirus Disease 2019 Vaccine-Related Lymphadenopathy on Lung Cancer Treatment.
Masago K, Fujita S.
J Thorac Oncol. 2022 Jan;17(1):16-18. doi: 10.1016/j.jtho.2021.10.002.
Nano-mediated strategy for targeting and treatment of non-small cell lung cancer (NSCLC).
Ashique S, Garg A, Mishra N, Raina N, Ming LC, Tulli HS, Behl T, Rani R, Gupta M.
Naunyn Schmiedebergs Arch Pharmacol. 2023 Nov;396(11):2769-2792. doi: 10.1007/s00210-023-02522-5. Epub 2023 May 23.
